Welcure Drugs & Pharmaceuticals Ltd (WELCURE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Welcure Drugs & Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Approval of the Audited Standalone Financial Results and Audited Standalone Financial Statements
Others (Uncategorized) · 02 Nov 2026, 11:15 pm
Welcure Drugs Reports FY26 Financials with Significant Auditor Disclosures Welcure Drugs & Pharmaceuticals approved corrected standalone results for the year ended 31st Mar'26, superseding its 29th May'26 filing. FY26 revenue surged to ₹38,952.44 lakh versus ₹2,455.00 lakh in FY25, driven entirely by the agriculture segment. However, the company posted a net loss of ₹567.08 lakh compared to a profit of ₹217.01 lakh in FY25. Statutory auditors issued an unmodified opinion with substantial emphasis of matters, noting unconfirmed supplier advances of ₹15,126.13 lakh, unverifiable sales invoices lacking e-way bills, and unverified inventory of ₹143,52.36 lakh.
Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Ltd held on today i.e. Tuesday, 14th July, 2026.
Others (Uncategorized) · 14 Jul 2026, 10:14 pm
Welcure Drugs to Close Ahmedabad Corporate Office Welcure Drugs & Pharmaceuticals' Board of Directors approved the closure of its Corporate Office in Ahmedabad, Gujarat, effective 14th Jul'26. The company stated the move is an administrative decision to improve operational efficiency and optimize resources. Business operations are expected to continue without interruption. All statutory records and books of account will be transferred to the company's Registered Office in New Delhi.
Resignation of Company Secretary and Compliance Officer
Change in Management · 19 Jun 2026, 9:37 pm
Welcure Drugs Announces Resignation of Company Secretary & Compliance Officer Welcure Drugs and Pharmaceuticals announced the resignation of Ms. Palak Jain from her roles as Company Secretary, Compliance Officer, and Key Managerial Personnel. The resignation is effective from the close of business on 19th Jun'26. The company stated the reason for her departure was personal reasons and other professional commitments. The Board of Directors has noted and accepted her resignation.
Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Friday, 19th June, 2026
Others (Uncategorized) · 19 Jun 2026, 9:32 pm
Welcure Drugs KMP Resigns Effective 19th Jun'26 Welcure Drugs & Pharmaceuticals announced the resignation of Ms. Palak Jain from her roles as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The board accepted her resignation, which is effective from the close of business on 19th Jun'26. The stated reason for her departure is personal reasons and other professional commitments.
Audited Standalone Financial Results for the Quarter and Year Ended 31st March, 2026
Financial Result · 30 May 2026, 1:39 am
Welcure Drugs FY26: Posts Net Loss Amid Auditor's Emphasis of Matter Welcure Drugs reported a net loss of Rs 549.01 Lacs for the year ended 31st Mar'26, against a profit of Rs 217.01 Lacs in the previous year. For Q4 FY26, the company posted a net loss of Rs 4,986.14 Lacs. The statutory auditor issued an unmodified opinion but included an "Emphasis of Matters" section, highlighting an inability to verify the existence and valuation of inventory (Rs 14,352.36 Lacs), genuineness of certain sales, and recoverability of trade receivables and unconfirmed supplier advances (Rs 15,126.13 Lacs).
Outcome of the Meeting of Board of Directors of the Company held on today i.e. Friday, 29th May, 2026
Outcome · 30 May 2026, 1:31 am
Welcure Drugs & Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 0.0 (-100.0% YoY) ■ EBITDA: -4,986 (Profit to Loss YoY | -147856.7% QoQ) ■ EBITDA Margin (%): 0.0 (-300 bps YoY) ■ PAT: -4,986 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.40 (Profit to Loss YoY | Profit to Loss QoQ) Welcure Drugs & Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) Segmental Performance Agriculture ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBITDA: -4,986 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): 0.0 (-1099 bps YoY | -9736 bps QoQ) Drugs and Pharmaceuticals ■ Revenue: 0.0 ■ EBITDA: 0.0 ■ EBITDA Margin (%): 0.0
Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial ....
Intimation · 29 May 2026, 5:30 am
Welcure Drugs Board Meeting on 29th May'26 for Q4 and FY26 Results Welcure Drugs & Pharmaceuticals has scheduled a Board of Directors meeting on 29th May'26. The agenda includes the consideration and approval of the audited financial results for the quarter and fiscal year ended 31st Mar'26. The board will also review and approve the audited financial statements, including the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement for the year. The statutory auditors' report on the financial results will also be taken on record.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 23 Apr 2026, 5:23 pm
Welcure Drugs Confirms It Is Not Classified as a Large Corporate Welcure Drugs & Pharmaceuticals confirmed on 23 Apr'26 that for the financial year ended 31 Mar'26, it does not meet the criteria to be classified as a "Large Corporate" under SEBI regulations. This determination exempts the company from the requirement to submit an annual disclosure in the format specified by the relevant SEBI circular. The company reported outstanding borrowings of ₹0.00 Cr as of the reporting date and holds no credit rating. BSE is the designated exchange.
Unaudited Financials Results for the 3rd Quarter ended on 31st December, 2025
Financial Result · 13 Feb 2026, 1:06 am
Welcure Drugs Reports Q3 FY26 Results; Profit After Tax Reaches ₹106.67 Lakhs Welcure Drugs and Pharmaceuticals reported unaudited financial results for Q3 FY26, posting a profit after tax of ₹106.67 lakhs. Total income for the quarter ended 31st Dec’25 stood at ₹146.43 lakhs, a significant QoQ decline from ₹6,562.40 lakhs. However, PAT grew 157% YoY from ₹41.50 lakhs. Profit before tax was ₹142.55 lakhs. The auditor's limited review report included a disclaimer of opinion, noting an inability to obtain sufficient evidence for their conclusion on the financial statements.
Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Thursday, 12th February, 2026
Outcome · 13 Feb 2026, 12:56 am
Welcure Drugs and Pharmaceuticals Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBITDA: -3.4 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): 0.0 (-1040 bps YoY | -1733 bps QoQ) ■ PAT: 107 (+157.0% YoY | -87.5% QoQ) ■ EPS (INR): 0.13 (+225.0% YoY | -82.9% QoQ) Welcure Drugs and Pharmaceuticals Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) Segmental Performance Agriculture ■ Revenue: 146 (-97.8% QoQ) ■ EBIT: 143 (-87.5% QoQ) ■ EBIT Margin (%): 97.4 (+8003 bps QoQ) Drugs and Pharmaceuticals ■ Revenue: 0.0 (-100.0% YoY) ■ EBIT: 0.0 (-100.0% YoY) ■ EBIT Margin (%): 0.0 (-1034 bps YoY)
Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve Un-audited ....
Intimation · 12 Feb 2026, 5:30 am
Welcure Drugs Schedules Board Meeting for Q3 FY26 Results Welcure Drugs & Pharmaceuticals has scheduled a Board of Directors meeting for 12 Feb'26 to consider and approve the un-audited financial results for the quarter and nine months ended 31 Dec'25. The company also confirmed that the trading window for designated persons has been closed from 01 Jan'26 until 48 hours after the declaration of the financial results.
Outcome of the Meeting of the Board of Directors of Welcure Drugs and Pharmaceuticals Limited held today i.e. Saturday, December 06, 2025
Others (Uncategorized) · 06 Dec 2025, 4:42 pm
Welcure Drugs Aborts Multiple Proposed Business Transactions and Projects At its board meeting on 06th Dec'25, Welcure Drugs and Pharmaceuticals Limited decided to abort several previously announced initiatives. The company has terminated a non-binding Letter of Intent for an equity investment from Telexcell Trade PTE LTD, Singapore, as a mutually acceptable framework could not be reached. It also decided not to proceed with the proposed Agro-Pharma Research Laboratory project and has consequently cancelled the associated fund-raising through a QIP. Furthermore, a definitive mandate for third-party sourcing and procurement services worth approximately ₹517 crore with Fortune Sagar Impex Company Limited, Thailand, has been discontinued. The company also confirmed that export-sourcing orders aggregating ₹299.91 crore were not executed as exports but were instead completed through domestic sales to the same parties.
Postponment of the meeting of the Right Issue Committe of the Welcure Drugs and Pharmaceuticals Limited which was to be held today i.e Monday,December 05,2025
Rights Issue · 05 Dec 2025, 10:34 pm
Welcure Drugs Postpones Rights Issue Committee Meeting Welcure Drugs and Pharmaceuticals Limited has postponed its Rights Issue Committee meeting, originally scheduled for 05th Dec'25. The meeting was intended to finalize key terms such as the record date, issue price, and entitlement ratio for its upcoming rights issue. The postponement is due to the pending in-principle approval from the stock exchange. The company will reschedule the meeting for the next working day after receiving the necessary approval.
Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/12/2025 ,inter alia, to consider and approve various matters ....
Intimation · 01 Dec 2025, 10:25 pm
Welcure Drugs to Finalize Terms for Rs. 49 Crore Rights Issue on Dec 5, 2025 Welcure Drugs and Pharmaceuticals Limited has scheduled a Rights Issue Committee meeting for 05th Dec'25 to determine the specific terms of its upcoming Rights Issue. The committee will decide on the issue price, payment mechanism, entitlement ratio, and record date. This follows the Board of Directors' approval on 01st Dec'25 for a Rights Issue of fully paid-up equity shares, aiming to raise an amount not exceeding Rs. 49,00,00,000. In accordance with insider trading regulations, the trading window for designated persons has been closed from 01st Dec'25 and will remain so until 48 hours after the meeting concludes.
Resignation of Independent Director of the Company
Change in Management · 01 Dec 2025, 5:15 pm
Welcure Drugs Announces Resignation of Independent Director Pradeep Terse Mr. Pradeep Dnyaneshwar Terse has resigned from his position as a Non-Executive Independent Director at Welcure Drugs and Pharmaceuticals Limited, effective from the close of business on 01st Dec'25. The company's board has accepted his resignation, which was tendered due to "pre-occupation with other matters." Mr. Terse confirmed there were no other material reasons for his departure.
Outcome of the Meeting of the Board of Directors of Welcure Drugs And Pharmaceuticals Limited held today i.e. Monday, December 01, 2025
Outcome · 01 Dec 2025, 5:13 pm
Welcure Drugs Board Approves Rs. 49 Crore Rights Issue and Accepts Director Resignation The Board of Directors of Welcure Drugs and Pharmaceuticals Limited, in a meeting on 01st Dec'25, approved a plan to raise up to Rs. 49 crores through a rights issue of equity shares with a face value of Rs. 1.00 each. The board also constituted a Rights Issue Committee to oversee the process and approved the Draft Letter of Offer. Additionally, the board accepted the resignation of Mr. Pradeep Dnyaneshwar Terse from his position as a Non-Executive Independent Director, effective 01st Dec'25, due to personal pre-occupation.
Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/12/2025 ,inter alia, to consider and approve To augment ....
Rescheduled / Cancelled · 27 Nov 2025, 6:02 pm
Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/11/2025 ,inter alia, to consider and approve Intimation ....
Intimation · 24 Nov 2025, 10:31 pm
Results-Unaudited Financial Statements For The Quarter And Half Year Ended 30th September 2025.
Financial Result · 13 Nov 2025, 11:12 pm
Outcome of the meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e Thursday,13th November 2025.
Outcome · 13 Nov 2025, 11:05 pm
Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve the Un-audited ....
Intimation · 13 Nov 2025, 5:30 am
Outcome of the Board Meeting-Allotment of Bonus Shares
Others (Uncategorized) · 17 Oct 2025, 6:40 pm
Fixation of Record Date for Stock Split/Sub-Division of Shares & Bonus issue.
Bonus Issue · 07 Oct 2025, 11:39 pm
Outcome of Board Meeting held on 07 October, 2025 of Welcure Pharmaceuticlas Limited.
Others (Uncategorized) · 07 Oct 2025, 11:35 pm
Voting Results of 33rd Annual General Meeting of Welcure Pharmaceutical Limited held on 27th September, 2025.
Annual General Meeting · 30 Sept 2025, 9:36 pm